A New T-287C Polymorphism in the 5’ Regulatory Region of the Tissue Factor Pathway Inhibitor Gene

Summary

Tissue factor pathway inhibitor (TFPI) is an important regulator of the extrinsic blood coagulation pathway. We screened the untranslated 5’ region of the TFPI gene for polymorphisms and investigated their possible involvement in arterial thrombosis. The allele frequencies of a new polymorphism, located 287 base pairs upstream of the transcription start site (T-287C), and that of the previously described C-399T polymorphism, were similar in cases and controls. In controls, the -287C allele was associated with significantly higher levels of total TFPI antigen, arguing for an effect of this polymorphism on TFPI gene expression. In controls, the C-399T polymorphism did not alter TFPI levels. In the cases, however, decreased total and post-heparin free TFPI levels and increased F1+2 levels were significantly associated with the -399T allele. These findings suggest that the T-287C and C-399T polymorphisms are not associated with an increased risk of coronary heart disease, a result which should be confirmed by a larger study. However, their influence on outcome, or a link with subtypes of acute coronary syndromes, cannot be excluded.

Keywords

Tissue factor pathway inhibitor - polymorphism - promoter - myocardial infarction - unstable angina

• References

• 1 Jude B, Agraou B, Mcfadden EP, Susen S, Bauters C, Lepelley P, Vanhaesbroucke C, Devos P, Cosson A, Asseman P. Evidence for time-dependent activation of monocytes in the systemic circulation in unstable angina but not in acute myocardial infarction or in stable angina. Circulation 1994; 90: 1662-8.
• 2 Soejima H, Ogawa H, Yasue H, Kaikita K, Nishiyama K, Misumi K, Takazoe K, Miyao Y, Yoshimura M, Kugiyama K, Nakamura S, Tsuji I, Kumeda K. Heightened tissue factor associated with tissue factor pathway inhibitor and prognosis in patients with unstable angina. Circulation 1999; 99: 2908-13.
• 3 Kaikita K, Takeya M, Ogawa H, Suefuji H, Yasue H, Takahashi K. Co-localization of tissue factor and tissue factor pathway inhibitor in coronary atherosclerosis. J Pathol 1999; 188: 180-8.
• 4 Caplice N, Mueske C, Kleppe L, Simari R. Presence of tissue factor pathway inhibitor in human atherosclerotic plaques is associated with reduced tissue factor activity. Circulation 1999; 98: 1051-7.
• 5 Broze Jr GJ. Tissue factor pathway inhibitor and the revised theory of coagulation. Annu Rev Med 1995; 46: 103-12.
• 6 van der Logt CPE, Reitsma PH, Bertina RM. Intron-Exon Organization of the Human Gene Coding for the Lipoprotein-Associated Coagulation Inhibitor – The Factor-Xa Dependent Inhibitor of the Extrinsic Pathway of Coagulation. Biochemistry 1991; 30: 1571-7.
• 7 Girard TJ, Eddy R, Wesselschmidt RL, Macphail LA, Likert KM, Byers MG, Shows TB, Broze GJ. Structure of the Human Lipoprotein-Associated Coagulation Inhibitor Gene – Intro/exon Gene Organization and Localization of the Gene to Chromosome-2. J Biol Chem 1991; 266: 5036-41.
• 8 Tyson DR, Kuppuswamy MN, Broze Jr GJ, Bajaj SP. Revised DNA sequence of exon 1 and 5’ flanking region of the human tissue factor pathway inhibitor gene. Thromb Res 1993; 70: 269-73.
• 9 Petit L, Lesnik P, Dachet C, Hugou I, Moreau M, Chapman J, Rouis M. The promoter of human tissue factor pathway inhibitor gene: identification of potential regulatory elements. Thromb Res 1999; 95: 255-62.
• 10 Lupu C, Poulsen E, Roquefeuil S, Westmuckett AD, Kakkar VV, Lupu F. Cellular effects of heparin on the production and release of tissue factor pathway inhibitor in human endothelial cells in culture. Arterioscler Thromb Vasc Biol 1999; 19: 2251-62.
• 11 Caplice N, Mueske C, Kleppe L, Peterson T, Broze GJ, Simari R. Expression of tissue factor pathway inhibitor in vascular smooth muscle cells and its regulation by growth factors. Circ Res 1998; 83: 1264-70.
• 12 Miyata T, Sakata T, Kumeda K, Uchida K, Tsushima M, Fujimura H, Kawasaki T, Kato H. C-399T polymorphism in the promoter region of human tissue factor pathway inhibitor (TFPI) gene does not change the plasma TFPI antigen level and does not cause venous thrombosis. Thromb Haemost 1998; 80: 345-6.
• 13 Moatti D, Seknadji P, Galand C, Poirier O, Fumeron F, Desprez S, Garbarz M, Dhermy D, Arveiler D, Evans A, Luc G, Ruidavets JB, Ollivier V, Hakim J, Aumont MC, De Prost D. Polymorphisms of the Tissue Factor Pathway Inhibitor (TFPI) Gene in Patients with Acute Coronary Syndromes and in Healthy Subjects: Impact of the V264M Substitution on Plasma Levels of TFPI. Arterioscler Thromb Vasc Biol 1999; 19: 862-9.
• 14 Bell G, Karam J, Rutter W. Polymorphic DNA region adjacent to the 5’ end of the human insulin gene. Proc Natl Acad Sci USA 1981; 78: 5759-63.
• 15 Bara L, Bloch ML, Zitoun D, Samama M, Collignon F, Frydman A, Uzan A, Bouthier J. Comparative effects of enoxaparin and unfractionated heparin in healthy volunteers on prothrombin consumption in whole blood during coagulation, and release of tissue factor pathway inhibitor. Thromb Res 1993; 69: 443-52.
• 16 Heinemeyer T, Chen X, Karas H, Kel AE, Kel OV, Liebich I, Meinhardt T, Reuter I, Schacherer F, Wingender E. Expanding the TRANSFAC database towards an expert system of regulatory molecular mechanism. Nucleic Acids Res 1999; 27: 318-22.
• 17 Lindahl A, Abildgaard U, Staalesen R. The anticoagulant effect in heparinized blood and plasma resulting from interactions with extrinsic pathway inhibitor. Thromb Res 1991; 64: 155-68.
• 18 Kamikura Y, Wada H, Yamada A, Shimura M, Hiyoyama K, Shiku H, Tanigawa M, Nishikawa H, Yamada N, Isaka N, Nakano T, Kumeda K, Kato H. Increased tissue factor pathway inhibitor in patients with acute myocardial infarction. Am J Hematol 1997; 55: 183-7.
• 19 Kokawa T, Enjyoji K, Kumeda K, Kamibuko Y, Harada-Shiba M, Koh H, Tsushima M, Yamamoto A, Kato H. Measurement of the free form of TFPI antigen in hyperlipidemia. Relationship between free and endothelial cellassociated forms of TFPI. Arterioscler Thromb Vasc Biol 1996; 16: 802-8.